Navigation Links
Prostate cancer immunotherapy significantly prolongs survival in men with advanced prostate cancer
Date:4/29/2009

CHICAGO, ILSipuleucel-T (Provenge), an experimental immunotherapy improved survival in men with metastatic disease, according to new results to be presented April 28 at the American Urological Association (AUA) Annual Scientific Meeting in Chicago. These data from the Phase 3 Immunotherapy for Prostate AdenoCarcinoma Treatment (IMPACT) study were presented during the meeting's Late Breaking Science Forum.

Compared to placebo, sipuleucel-T extended median survival by 4.1 months and improved three-year survival by 38 percent. Sipuleucel-T successfully exceeded the pre-specified level of statistical significance defined by the study's design and reduced the overall risk of death by 22.5 percent compared to placebo (p-value=0.032). More than 500 patients were enrolled in the IMPACT trial, a multi-center, randomized, double-blind, placebo-controlled study evaluating men with asymptomatic or minimally symptomatic, metastatic, androgen-independent prostate cancer. The primary endpoint was overall survival.

Researchers are encouraged by the findings, citing an impressive effect on long-term survival for patients, compared to placebo.

"The ability to boost survival for patients is the gold standard endpoint in prostate cancer clinical trials," said AUA spokesperson Ira D. Sharlip, MD. "The ability to give these patients both increased survival and possibly, improved quality of life, is very important."

Sipuleucel-T is an investigational therapy for men with androgen-independent prostate cancer. It is an active cellular immunotherapy designed to use live human cells to boost a patient's immune system to elicit a long-lasting response against cancer.


'/>"/>

Contact: Wendy Isett
wisett@auanet.org
410-977-4770
American Urological Association
Source:Eurekalert

Page: 1

Related medicine news :

1. Statins alter prostate cancer patients PSA levels
2. Living and Loving with Prostate Cancer: Men Deserve Better
3. Data Show Dutasteride Reduces Prostate Cancer Diagnosis in Men With Increased Risk
4. AUA Counters Mainstream Recommendations with New Best Practice Statement on Prostate-Specific Antigen Testing
5. Heart, Bone Problems May Follow Prostate Cancer Treatment
6. Prostate Study Shows BOTOX May Be Safe, Effective Method for Managing Benign Prostatic Hyperplasia
7. Prostate cancer therapy increases risk of fractures and cardiovascular-related death
8. Statins Guard Against Prostate Cancer
9. Statins may exert influence on prostate cancer growth by reducing inflammation
10. Major statin study reveals several important findings for reducing prostate cancer and disease
11. Varian Medical Systems to Exhibit Full Spectrum of Prostate Cancer Treatment Technologies at the American Urological Association Meeting in Chicago
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2017)... Jacksonville, Fla. (PRWEB) , ... July 25, 2017 , ... ... employee and father Ezra Clark is taking advantage of a new benefit for employees ... “It really means a lot that the company supports me and other employees as ...
(Date:7/25/2017)... ... July 25, 2017 , ... SignatureCare Emergency Center – South ... TX area 24 Hours a day. , The Emergency Room opened ... “We’ve been open four months now and things are running smoothly,” said Aaron Braun, ...
(Date:7/24/2017)... ... July 24, 2017 , ... ... , Robins & Morton, Perkins Will, Newcomb & Boyd, Walter P Moore ... the new Destination Medical Building located at Mayo Clinic in Jacksonville, Florida. ...
(Date:7/24/2017)... ... July 24, 2017 , ... SignatureCare Emergency Center is looking to ... fall semester to a deserving student. Get your applications in now as the ... to Mariana Castillo who is a nursing student at Prairie View A&M University with ...
(Date:7/24/2017)... ... July 24, 2017 , ... ... Abuse and Mental Health Services Administration’s (SAMHSA) State Targeted Response to the Opioid ... Health Care Services, will facilitate the development of a hub and spoke model ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)... 2017  Sysmex America, Inc., a leading provider ... as well as middleware information systems technology, today ... quality assurance easier and more risk free than ... for the innovation that it delivers to the ... assurance processes to a new level with automated, ...
(Date:7/11/2017)... 11, 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... company focused on the development of oral drug delivery ... Administration (FDA) has agreed to schedule an End-of-Phase II ... trial of its oral insulin capsule ORMD-0801 in the ... met primary and secondary endpoints by indicating a statistically ...
(Date:7/10/2017)... -- The Institute for In Vitro Sciences (IIVS), a ... a VITROCELL® inhalation exposure system thanks to a generous ... which is designed to replace animals in inhalation testing, ... airborne test materials in an environment that mimics the ... testing combustible tobacco products, as well as next generation ...
Breaking Medicine Technology: